Revvity (NYSE:RVTY) Posts Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Revvity (NYSE:RVTY) released its quarterly earnings results on Tuesday. The company reported $1.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.30 by $0.08, Zacks reports. The company had revenue of $728.90 million during the quarter, compared to the consensus estimate of $694.73 million. Revvity had a return on equity of 8.34% and a net margin of 8.16%. The firm’s revenue was up 4.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.18 EPS.

Here are the key takeaways from Revvity’s conference call:

• Revvity exceeded expectations in Q3, delivering 7% pro forma organic growth, 29.4% adjusted operating margins, and adjusted EPS of $1.37, $0.08 above the midpoint of its guidance.
• Life sciences organic growth reached 9%, led by high-single-digit reagent growth, mid-single-digit instrument growth, and upper-teens Signals Software growth. Management cited improving pharma and biotech demand, expanding AI-related activity, and growing instrument backlogs, particularly in high-content screening.
• The company raised its full-year outlook to approximately 5% pro forma organic growth and $5.40–$5.45 adjusted EPS, while increasing its operating-margin forecast to 28.8%. Efficiency initiatives and favorable mix are supporting more than 40% incremental margins.
• Diagnostics grew 5% organically, with margins reaching 29.9%; excluding the China immunodiagnostics business targeted for divestiture, margins exceeded 30%. Revvity also launched a type 1 diabetes screening assay in Europe, but reproductive health remains constrained by weak Chinese birth rates.
• Management expects some moderation in Q4 growth, partly because reagent bulk orders shifted into Q3 and Signals Software growth is expected to slow from the high teens to the mid-teens. AI demand is broadening but remains in its early stages, and the company expects no share repurchases in its Q4 guidance.

Revvity Stock Performance

Revvity stock traded up $19.10 during mid-day trading on Tuesday, reaching $170.70. The company had a trading volume of 1,498,976 shares, compared to its average volume of 1,526,289. The company has a quick ratio of 1.50, a current ratio of 1.80 and a debt-to-equity ratio of 0.36. The firm has a market cap of $19.05 billion, a price-to-earnings ratio of 80.79, a PEG ratio of 3.01 and a beta of 1.06. The company has a 50 day moving average of $145.08 and a 200-day moving average of $112.36. Revvity has a 52 week low of $81.22 and a 52 week high of $171.74.

Revvity Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 12th. Stockholders of record on Friday, January 22nd will be issued a dividend of $0.07 per share. The ex-dividend date is Friday, January 22nd. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.2%. Revvity’s payout ratio is 13.33%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Weiss Ratings raised Revvity from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. Evercore reiterated an “outperform” rating on shares of Revvity in a report on Wednesday, August 5th. KeyCorp increased their price target on Revvity from $125.00 to $165.00 and gave the company an “overweight” rating in a report on Friday, September 4th. UBS Group began coverage on shares of Revvity in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $140.00 price target on the stock. Finally, Zacks Research upgraded shares of Revvity from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. Five equities research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $124.43.

Insider Activity

In other news, insider Maxwell Krakowiak sold 1,631 shares of the company’s stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $144.53, for a total value of $235,728.43. Following the sale, the insider directly owned 14,781 shares in the company, valued at approximately $2,136,297.93. This represents a 9.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Tajinder S. Vohra sold 7,330 shares of the company’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $140.88, for a total value of $1,032,650.40. Following the completion of the sale, the insider owned 6,635 shares in the company, valued at $934,738.80. This trade represents a 52.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 9,045 shares of company stock worth $1,281,439 over the last 90 days. Corporate insiders own 0.85% of the company’s stock.

About Revvity

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.